Filippo De Braud
Overview
Explore the profile of Filippo De Braud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
471
Citations
14287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez-Rosas P, Nagy M, Spronk H, Russo L, Gamba S, Tartari C, et al.
J Thromb Haemost
. 2025 Mar;
PMID: 40056983
Background: Non-small cell lung cancer (NSCLC) patients are at high risk of venous thromboembolism (VTE), especially during chemotherapy. Even though the contact system is implicated in the pathogenesis of thrombosis,...
2.
Pal S, Bernard-Tessier A, Grell P, Gao X, Kotecha R, Picus J, et al.
Clin Cancer Res
. 2025 Mar;
PMID: 40043000
Background: Mutations or silencing of the von Hippel Lindau (VHL) tumor suppressor gene accumulates hypoxia-inducible factors (HIFs). HIF-2α is implicated in the oncogenesis of ~50% of patients with clear cell...
3.
Gautschi O, Park K, Solomon B, Tomasini P, Loong H, De Braud F, et al.
J Clin Oncol
. 2025 Feb;
:JCO2402076.
PMID: 39983053
LIBRETTO-001 (ClinicalTrials.gov identifier: NCT03157128) is a registrational phase I/II, single-arm, open-label trial of selpercatinib in RET-dependent cancers. With 19 months of additional follow-up, we report the final efficacy and safety...
4.
Dagna L, Alunno A, Farina N, Agnelli G, Borghi C, Caporali R, et al.
Eur J Intern Med
. 2025 Feb;
PMID: 39979142
Introduction: JAK inhibitors (JAKi) have emerged as effective treatments for chronic inflammatory diseases, including gastrointestinal, dermatological, and rheumatological conditions. Despite their efficacy, concerns about their safety profile necessitate a comprehensive...
5.
Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, et al.
Eur J Cancer
. 2025 Jan;
216:115122.
PMID: 39793445
Purpose: MAK683, a first-in-class and highly selective allosteric inhibitor of the embryonic ectoderm development subunit of polycomb repressive complex 2, has shown sustained antitumor activity in tumor xenograft models. This...
6.
Favalli E, Grossi F, Batticciotto A, Filippini M, Parisi S, Viapiana O, et al.
Rheumatol Ther
. 2024 Dec;
12(1):25-36.
PMID: 39718763
Current literature regarding cancer risk in rheumatic and musculoskeletal diseases (RMDs) is particularly poor and controversial, even though the incidence of malignancy in some patients with RMDs is considered to...
7.
Ligorio F, Vingiani A, Torelli T, Sposetti C, Drufuca L, Iannelli F, et al.
Cell Metab
. 2024 Dec;
37(2):330-344.e7.
PMID: 39694040
In preclinical experiments, cyclic fasting-mimicking diets (FMDs) showed broad anticancer effects in combination with chemotherapy. Among different tumor types, triple-negative breast cancer (TNBC) is exquisitely sensitive to FMD. However, the...
8.
Filetti M, Occhipinti M, Cirillo A, Scirocchi F, Ugolini A, Giusti R, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682144
: Single-agent immune checkpoint inhibitor (IO) therapy is the standard for non-oncogene-addicted advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumor proportion score ≥ 50%. Smoking-induced harm generates high tumor...
9.
Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, et al.
Cancer Med
. 2024 Dec;
13(23):e70393.
PMID: 39618336
Background: The identification of actionable molecular targets of pancreatic cancer (PAC) is key to improving patient outcomes. We hypothesized O6-methylguanine-DNA methyltransferase (MGMT) silencing may occur in a subset of PAC...
10.
Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, et al.
Crit Rev Oncol Hematol
. 2024 Sep;
204:104521.
PMID: 39317528
No abstract available.